Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure.

Abstract

Elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease (CVD) in patients with chronic renal failure (CRF). The phosphate-binder sevelamer has been shown to decrease both phosphate and FGF23, but limited data indicate that sevelamer improves CRF-related CVD, such as diastolic dysfunction, left… (More)
DOI: 10.1038/ki.2013.110

7 Figures and Tables

Topics

  • Presentations referencing similar topics